Risk of COVID‐19 death for people with a pre‐existing cancer diagnosis prior to COVID‐19‐vaccination: A systematic review and meta‐analysis
Authors: Steinberg Julia , Hughes Suzanne , Hui Harriet , Allsop Matthew J. , Egger Sam , David Michael , Caruana Michael , Coxeter Peter , Carle Chelsea , Onyeka Tonia , Rewais Isabel , Monroy Iglesias Maria J. , Vives Nuria , Wei Feixue , Abila Derrick Bary , Carreras Giulia , Santero Marilina , O'Dowd Emma L. , Lui Gigi , Tolani Musliu Adetola , Mullooly Maeve , Lee Shing Fung , Landy Rebecca , Hanley Sharon J. B. , Binefa Gemma , McShane Charlene M. , Gizaw Muluken , Selvamuthu Poongulali , Boukheris Houda , Nakaganda Annet , Ergin Isil , Moraes Fabio Ynoe , Timilshina Nahari , Kumar Ashutosh , Vale Diama B. , Molina‐Barceló Ana , Force Lisa M. , Campbell Denise Joan , Wang Yuqing , Wan Fang , Baker Anna‐Lisa , Singh Ramnik , Salam Rehana Abdus , Yuill Susan , Shah Richa , Lansdorp‐Vogelaar Iris , Yusuf Aasim , Aggarwal Ajay , Murillo Raul , Torode Julie S. , Kliewer Erich V. , Bray Freddie , Chan Kelvin K. W. , Peacock Stuart , Hanna Timothy P. , Ginsburg Ophira , Van Hemelrijck Mieke , Sullivan Richard , Roitberg Felipe , Ilbawi André M. , Soerjomataram Isabelle , Canfell Karen 
Published: December 2023

AbstractWhile previous reviews found a positive association between pre‐existing cancer diagnosis and COVID‐19‐related death, most early studies did not distinguish long‐term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher‐quality evidence on risk of COVID‐19‐related death for people with recent/active cancer (compared to people without) in the pre‐COVID‐19‐vaccination period. We searched the WHO COVID‐19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk‐of‐bias assessment was based on the Newcastle‐Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse‐variance random‐effects models. Random‐effects meta‐regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23 773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID‐19‐related death was higher for people with active or recently diagnosed/treated cancer (general population: aOR = 1.48, 95% CI: 1.36‐1.61, I2 = 0; people with COVID‐19: aOR = 1.58, 95% CI: 1.41‐1.77, I2 = 0.58; inpatients with COVID‐19: aOR = 1.66, 95% CI: 1.34‐2.06, I2 = 0.98). Risks were more elevated for lung (general population: aOR = 3.4, 95% CI: 2.4‐4.7) and hematological cancers (general population: aOR = 2.13, 95% CI: 1.68‐2.68, I2 = 0.43), and for metastatic cancers. Meta‐regression suggested risk of COVID‐19‐related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR = 1.55 (95% CI: 1.37‐1.75) at 1 year and aOR = 0.98 (95% CI: 0.80‐1.20) at 5 years post‐cancer diagnosis/treatment. In conclusion, before COVID‐19‐vaccination, risk of COVID‐19‐related death was higher for people with recent cancer, with risk depending on cancer type and time since diagnosis/treatment.